| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/20/1999 | CA2308361A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/20/1999 | CA2308359A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/20/1999 | CA2308358A1 Heterocyclic compounds having mmp and tnf inhibitory activity |
| 05/20/1999 | CA2308269A1 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
| 05/20/1999 | CA2307210A1 Anti-estrogen plus progestin containing oral contraceptives |
| 05/20/1999 | CA2306477A1 Azaring-ether derivatives and their use as nicotinic ach receptor modulators |
| 05/20/1999 | CA2306465A1 Piperazine-cyclodextrin complexes |
| 05/20/1999 | CA2306155A1 Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| 05/20/1999 | CA2303959A1 Oxazolidinone derivatives and pharmaceutical compositions |
| 05/19/1999 | EP0916737A2 Polynucleotide compounds for hybridizing to target polynucleotides |
| 05/19/1999 | EP0916729A2 Novel reductase |
| 05/19/1999 | EP0916727A2 Novel LysS |
| 05/19/1999 | EP0916680A2 Lantibiotic related to Actagardine, process of preparation and use thereof |
| 05/19/1999 | EP0916679A1 Benzazepinone-N-acetic acid derivatives having a phosphonic acid group, process for their preparation and medicaments containing these compounds |
| 05/19/1999 | EP0916678A2 Method of clotting blood |
| 05/19/1999 | EP0916675A2 Process for preparing sildenafil |
| 05/19/1999 | EP0916673A1 6-Amino purine derivatives having PDE-IV inhibition activity |
| 05/19/1999 | EP0916672A1 6-Amino purine derivatives having PDE-IV inhibition activity and intermediates |
| 05/19/1999 | EP0916671A1 Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 05/19/1999 | EP0916670A2 Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists |
| 05/19/1999 | EP0916666A1 3-alkyloxy-,aryloxy-, or arylalkyloxy-benzo[b]thiophene-2-carboxamides as inhibitors of cell adhesion |
| 05/19/1999 | EP0916663A1 18Beta, 19Beta-diacetyloxy-18Alpha, 19Alpha-epoxy-3,13(16), 14-clerodatrien-2-one (Esculentin A) and 18Beta, 19Beta-diacetyloxy-18Alpha, 19Alpha-epoxy-3, 12, 14-clerodatrien-2Beta-isovaleryloxy-6Beta, 7Alpha-diol (Esculentin B), a process for their preparation, and their use in the manufacture of medicaments |
| 05/19/1999 | EP0916662A2 Ascorbylsorbate |
| 05/19/1999 | EP0916657A1 1-phenylpyrrolidone derivatives having optical activity |
| 05/19/1999 | EP0916652A1 N-Aryl 2-hydroxy alkylamides |
| 05/19/1999 | EP0916651A1 Phenylalkylcarboxylic acid derivatives |
| 05/19/1999 | EP0916647A2 Hydrophilic agent, process for producing it and his use as dispersing agent for aqueous polyurethane dispersions |
| 05/19/1999 | EP0916349A2 Method for monitoring cellular oxidative function |
| 05/19/1999 | EP0916347A1 Pharmaceutical injectable solutions containing paracetamol and combinations of paracetamol with other active substances |
| 05/19/1999 | EP0916346A2 NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
| 05/19/1999 | EP0916343A1 use of alkzl phosphoric acid compounds for the treatment of psoriatic diseases |
| 05/19/1999 | EP0916342A1 A medicament for treating obesity and improving lipid metabolism |
| 05/19/1999 | EP0916341A2 Synergistic pharmaceutical compositions containing triamcinolone acetonide and halcinonide |
| 05/19/1999 | EP0916340A1 Suppositories |
| 05/19/1999 | EP0916339A1 Prolonged activity nicotine patch |
| 05/19/1999 | EP0916338A1 Antirheumatic agent |
| 05/19/1999 | EP0916337A2 Use of inhibitors of the sodium-hydrogen exchange in the manufacture of amedicament for reducing unwanted effects of compounds on the heart. |
| 05/19/1999 | EP0916336A1 Transdermal delivery system |
| 05/19/1999 | EP0916335A2 Cosmetic and parmaceutical compositions containing a photostable UV filter |
| 05/19/1999 | EP0915978A2 Dna immunization against chlamydia infection |
| 05/19/1999 | EP0915977A1 B. burgdorferi polypeptides expressed in vivo |
| 05/19/1999 | EP0915973A1 Gene involved in cadasil, method of diagnosis and therapeutic application |
| 05/19/1999 | EP0915969A1 Method for preventing hiv-1 infection of cd4+ cells |
| 05/19/1999 | EP0915904A1 Mammalian sex comb on midleg (mammalian scm) acts as a tumor suppressor |
| 05/19/1999 | EP0915899A1 Preparation of crystal form ii of clarithromycin |
| 05/19/1999 | EP0915898A1 Crystal form i of clarithromycin |
| 05/19/1999 | EP0915895A1 New salts of anionic complexes of ru(iii), as antimetastatic and antineoplastic agents |
| 05/19/1999 | EP0915887A1 Substituted n-isothiazolyl-(thio)amides |
| 05/19/1999 | EP0915882A1 1-azoniabicyclo[2.2.1]heptane derivatives and pharmaceutical compositions containing them |
| 05/19/1999 | EP0915881A1 Pyrroloazepine compounds |
| 05/19/1999 | EP0915880A1 Azolo triazines and pyrimidines |
| 05/19/1999 | EP0915879A1 Novel compounds |
| 05/19/1999 | EP0915877A1 SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABA A?$g(a)5 RECEPTOR SUBTYPE |
| 05/19/1999 | EP0915876A1 Tricyclic benzazepine vasopressin antagonists |
| 05/19/1999 | EP0915875A2 Substituted triazolo-pyridazine derivatives as ligands for gaba receptors |
| 05/19/1999 | EP0915872A1 Substituted bisindolylmaleimides for the inhibition of cell proliferation |
| 05/19/1999 | EP0915871A1 Substituted bisindolylmaleimides for the inhibition of cell proliferation |
| 05/19/1999 | EP0915870A1 Substituted bisindolylmaleimides for the inhibition of cell proliferation |
| 05/19/1999 | EP0915869A1 Novel tricyclic n-cyanoimines useful as inhibitors of farnesyl-protein transferase |
| 05/19/1999 | EP0915864A1 Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease |
| 05/19/1999 | EP0915860A1 Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands |
| 05/19/1999 | EP0915859A1 Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
| 05/19/1999 | EP0915857A1 Compounds of the 3-aryl 2,4 dioxo oxazolidine family and use thereof in cosmetics and pharmaceuticals |
| 05/19/1999 | EP0915856A1 Diphenyl heterocycles as potassium channel modulators |
| 05/19/1999 | EP0915855A1 Novel compounds with analgesic effect |
| 05/19/1999 | EP0915850A1 Novel carbocyclic diarylmethylene derivatives, methods for preparing same, and therapeutical uses thereof |
| 05/19/1999 | EP0915848A1 1,2-diarylindole as cox-2 inhibitors |
| 05/19/1999 | EP0915847A1 Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity |
| 05/19/1999 | EP0915845A1 Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents |
| 05/19/1999 | EP0915843A1 Azetidinone derivatives for the treatment of atheroscleroses |
| 05/19/1999 | EP0915842A1 Nitrate esters and their use for neurological conditions |
| 05/19/1999 | EP0915841A1 Anilinopeptide derivatives |
| 05/19/1999 | EP0915834A1 Method and compositions for producing analgesia |
| 05/19/1999 | EP0915830A1 Benzoylpropionic acid ester derivatives |
| 05/19/1999 | EP0915826A1 Smooth muscle spasmolytic agents, compositions and methods of use thereof |
| 05/19/1999 | EP0915825A2 Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| 05/19/1999 | EP0915823A1 Bi-aromatic compounds, pharmaceutical and cosmetic compositions containing same and uses |
| 05/19/1999 | EP0915819A1 Illudin analogs useful as antitumor agents |
| 05/19/1999 | EP0915705A1 Ionic polymers as anti-infective agents |
| 05/19/1999 | EP0915704A1 Use of phosphinyloxyalkyl and phosphonamidoalkyl derivatives of cyclopentane(ene) as therapeutic agents |
| 05/19/1999 | EP0915703A1 Combinations of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum |
| 05/19/1999 | EP0915702A2 Use of a dehydroepiandrosterone derivative for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue |
| 05/19/1999 | EP0915701A1 Fast-dissolving galanthamine hydrobromide tablet |
| 05/19/1999 | EP0915700A1 Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors |
| 05/19/1999 | EP0915698A1 Therapeutic treatment for vegf related diseases |
| 05/19/1999 | EP0915697A2 Anticonvulsant sulfamate derivatives useful in treating obesity |
| 05/19/1999 | EP0915696A2 ANTI-beta-AMYLOID PROTEIN-INDUCED CYTOTOXICITY COMPOSITION |
| 05/19/1999 | EP0915651A1 Il-8 receptor antagonists |
| 05/19/1999 | EP0915650A1 A method for minimizing the uterotrophic effect of droloxifene |
| 05/19/1999 | EP0835120B1 Pharmaceutical compositions containing herbal-based active ingredients; method for preparing same and uses of same for medical and veterinary purposes |
| 05/19/1999 | EP0804456A4 Peptide nucleic acid conjugates |
| 05/19/1999 | EP0772440A4 Carbon monoxide dependent guanylyl cyclase modifiers |
| 05/19/1999 | EP0756477A4 Methods for phototherapeutic treatment of proliferative skin diseases |
| 05/19/1999 | EP0752986B1 N-heterocyclyl sulphonamide derivatives and their use as endothelin antagonists |
| 05/19/1999 | EP0745596B1 Heteroaromatic oxazole compounds and use thereof |
| 05/19/1999 | EP0730575B1 Novel carbamate compounds and processes for preparing the same |
| 05/19/1999 | EP0720599B1 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| 05/19/1999 | EP0666857B1 Method for preparing taxane derivatives |
| 05/19/1999 | EP0662837B1 Use of il-10 to prevent insulin-dependent diabetes mellitus |
| 05/19/1999 | EP0633887B1 Calanolide antiviral compounds, compositions and uses thereof |